Evolent Health
EVH
209 hedge funds and large institutions have $2.64B invested in Evolent Health in 2021 Q3 according to their latest regulatory filings, with 45 funds opening new positions, 50 increasing their positions, 80 reducing their positions, and 13 closing their positions.
348% more call options, than puts
Call options by funds: $62M | Put options by funds: $13.9M
246% more first-time investments, than exits
New positions opened: 45 | Existing positions closed: 13
80% more funds holding in top 10
Funds holding in top 10: 5 → 9 (+4)
51% more capital invested
Capital invested by funds: $1.75B → $2.64B (+$895M)
17% more funds holding
Funds holding: 178 → 209 (+31)
2.59% more ownership
Funds ownership: 95.53% → 98.12% (+2.6%)
38% less repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 80
Top Buyers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$68M |
| 2 |
Loomis, Sayles & Company
Boston,
Massachusetts
|
+$17.2M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
+$10.1M |
| 4 |
TAL
TIG Advisors LLC
New York
|
+$9.03M |
| 5 |
IM
Islet Management
New York
|
+$8.4M |
Top Sellers
| 1 |
EC
Engaged Capital
Newport Beach,
California
|
-$15.8M |
| 2 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
-$14.5M |
| 3 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$10.5M |
| 4 |
SAM
Silvercrest Asset Management
New York
|
-$8.39M |
| 5 |
Two Sigma Advisers
New York
|
-$7.74M |
EVH Hedge Fund Activity: Q3 2021 in Review
209 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Evolent Health (EVH) for Q3 2021, worth a combined $2.64B — up 51% from $1.75B a quarter earlier.
Buyers outnumbered sellers: 45 funds opened new EVH positions and 13 closed out — a net gain of 32 holders — while 50 added to existing stakes and 80 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $68M. The largest seller was Engaged Capital, cutting an estimated $15.8M.
- 209 institutional investors held Evolent Health (EVH) as of Q3 2021, up from 178 in Q2 2021.
- Funds reported $2.64B of Evolent Health stock for Q3 2021, up 51% quarter-over-quarter.
- 45 funds opened new Evolent Health positions in Q3 2021 and 13 closed out, a net change of +32 holders.
- The largest Evolent Health buyer in Q3 2021 was Fidelity Investments, an estimated $68M added.
- The largest Evolent Health seller in Q3 2021 was Engaged Capital, an estimated $15.8M sold.
Based on aggregated 13F filings for Q3 2021.